Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.021
Neutral
RSI(14)
59.847
Neutral
STOCH(KDJ)(9,3,3)
55.086
Neutral
ATR(14)
0.462
Low Volatility
CCI(14)
26.497
Neutral
Williams %R
54.962
Neutral
TRIX(12,20)
0.390
Sell
StochRSI(14)
36.526
Buy
Bausch + Lomb Corp
BLCO16.950USD
+0.050+0.30%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
6.00BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bausch + Lomb Corp
Currency: USD Updated: 2025-12-19Key Insights
Bausch + Lomb Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 74/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 17.15.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bausch + Lomb Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Hold
Current Rating
17.154
Target Price
+3.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bausch + Lomb Corp Highlights
StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.
Fairly Valued
The company’s latest PE is -19.69, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.63M shares, increasing 0.03% quarter-over-quarter.
Held by Howard Marks
Star Investor Howard Marks holds 3.25M shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Bausch + Lomb Corp is 6.39, ranking 158/208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.28B, representing a year-over-year increase of 7.11%, while its net profit experienced a year-over-year increase of 800.00%.
Score
Financials
5.33
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.53
Operational Efficiency
8.70
Growth Potential
8.10
Shareholder Returns
7.28
Bausch + Lomb Corp's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Bausch + Lomb Corp is 8.63, ranking 15/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -19.69, which is -5703.01% below the recent high of 1103.27 and -237.90% above the recent low of -66.53.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 74/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Bausch + Lomb Corp is 6.86, ranking 160/208 in the Healthcare Equipment & Supplies industry. The average price target for Bausch + Lomb Corp is 17.00, with a high of 21.00 and a low of 13.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
17.154
Target Price
+3.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Bausch + Lomb Corp
BLCO
14
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Bausch + Lomb Corp is 9.11, ranking 30/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 18.27 and the support level at 15.11, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
16.966
Sell
MA10
16.885
Buy
MA20
16.592
Buy
MA50
15.843
Buy
MA100
15.237
Buy
MA200
14.129
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Bausch Health Companies Inc
Deutsche Bank Securities Inc.
Alberta Investment Management Corporation
GoldenTree Asset Management, LP
D. E. Shaw & Co., L.P.
Fidelity Management & Research Company LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Bausch + Lomb Corp is 7.44, ranking 36/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.59
VaR
--
240-Day Maximum Drawdown
+39.71%
240-Day Volatility
+46.42%
Return
Best Daily Return
60 days
+5.00%
120 days
+5.25%
5 years
--
Worst Daily Return
60 days
-5.48%
120 days
-6.42%
5 years
--
Sharpe Ratio
60 days
+1.64
120 days
+1.86
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+39.71%
3 years
+48.07%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.10
3 years
-0.02
5 years
--
Skewness
240 days
-0.60
3 years
+0.14
5 years
--
Volatility
Realised Volatility
240 days
+46.42%
5 years
--
Standardised True Range
240 days
+3.04%
5 years
--
Downside Risk-Adjusted Return
120 days
+308.53%
240 days
+308.53%
Maximum Daily Upside Volatility
60 days
+27.49%
Maximum Daily Downside Volatility
60 days
+22.19%
Liquidity
Average Turnover Rate
60 days
+0.22%
120 days
+0.23%
5 years
--
Turnover Deviation
20 days
+8.03%
60 days
+26.09%
120 days
+31.29%
Peer Comparison
Healthcare Equipment & Supplies
Bausch + Lomb Corp
BLCO
7.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Bausch + Lomb Corp?
The TradingKey Stock Score provides a comprehensive assessment of Bausch + Lomb Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Bausch + Lomb Corp’s performance and outlook.
How do we generate the financial health score of Bausch + Lomb Corp?
To generate the financial health score of Bausch + Lomb Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Bausch + Lomb Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Bausch + Lomb Corp.
How do we generate the company valuation score of Bausch + Lomb Corp?
To generate the company valuation score of Bausch + Lomb Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Bausch + Lomb Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Bausch + Lomb Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Bausch + Lomb Corp.
How do we generate the earnings forecast score of Bausch + Lomb Corp?
To calculate the earnings forecast score of Bausch + Lomb Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Bausch + Lomb Corp’s future.
How do we generate the price momentum score of Bausch + Lomb Corp?
When generating the price momentum score for Bausch + Lomb Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Bausch + Lomb Corp’s prices. A higher score indicates a more stable short-term price trend for Bausch + Lomb Corp.
How do we generate the institutional confidence score of Bausch + Lomb Corp?
To generate the institutional confidence score of Bausch + Lomb Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Bausch + Lomb Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Bausch + Lomb Corp.
How do we generate the risk management score of Bausch + Lomb Corp?
To assess the risk management score of Bausch + Lomb Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Bausch + Lomb Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Bausch + Lomb Corp.
